Compare Stocks → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:ONC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeONCOncolytics BiotechC$1.45+5.1%C$1.46C$1.20▼C$4.49C$109.36M1.4975,475 shs83,473 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceONCOncolytics Biotech+5.07%+4.32%+1.40%-18.99%-9.94%Warning: this could blow your mind (Ad)Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationONCOncolytics Biotech0.4473 of 5 stars3.50.00.00.00.00.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceONCOncolytics Biotech3.00BuyC$9.00520.69% UpsideCurrent Analyst RatingsLatest ONC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails1/12/2024ONCOncolytics BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookONCOncolytics BiotechN/AN/AC$0.34 per share4.22C$0.37 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateONCOncolytics Biotech-C$27.75M-C$0.41N/A∞N/AN/A-102.66%-55.47%5/3/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthONCOncolytics BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioONCOncolytics Biotech1.549.018.86OwnershipInstitutional OwnershipCompanyInstitutional OwnershipONCOncolytics Biotech6.98%Insider OwnershipCompanyInsider OwnershipONCOncolytics Biotech1.14%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableONCOncolytics Biotech2975.42 millionN/ANot OptionableONC HeadlinesSourceHeadlineClosing Bell: Oncolytics Bio down on Friday (ONC)theglobeandmail.com - March 16 at 10:14 AMFutures Retreat Sharplymsn.com - March 11 at 4:05 PMOncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANfinanznachrichten.de - March 6 at 4:39 PMEcon Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winningfinanznachrichten.de - March 6 at 4:39 PMA Preview Of Oncolytics Biotech's Earningsbenzinga.com - March 6 at 4:39 PMOncolytics Biotech (ONC) Set to Announce Earnings on Thursdaymarketbeat.com - March 5 at 10:10 AMOncolytics Biotech Inc ONCmorningstar.com - March 2 at 6:22 PMReiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s Pipelinemarkets.businessinsider.com - February 15 at 9:24 AMCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatmentsfinance.yahoo.com - February 15 at 9:24 AMAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapiestheglobeandmail.com - February 14 at 2:36 PMUSA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024finanznachrichten.de - February 7 at 11:03 AMKaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Virusesfinance.yahoo.com - January 31 at 8:47 PMOncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, Predictionsbenzinga.com - January 6 at 3:30 PMJonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)markets.businessinsider.com - December 14 at 8:26 AMOncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCSfinanznachrichten.de - December 7 at 8:30 AMOncolytics Provides Update on Pancreatic Cancer Program for Pelareorepfinance.yahoo.com - November 9 at 7:48 AMOncolytics Biotech's Earnings Outlookbenzinga.com - November 3 at 6:37 PMOncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational Highlightsfinanznachrichten.de - November 3 at 1:36 PMOncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITCfinanznachrichten.de - November 3 at 1:36 PMOncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITCfinance.yahoo.com - November 3 at 1:36 PMOncolytics Biotech GAAP EPS of -$0.14 misses by $0.06msn.com - November 3 at 8:36 AMOncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlightsfinance.yahoo.com - November 3 at 8:36 AMOncolytics Shares Rise 9.3% as Data Presented From Pancreatic Cancer Studymarketwatch.com - October 23 at 8:38 PMUSA News Group: Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Researchfinanznachrichten.de - October 20 at 12:48 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesMastering Stocks in the Dow: Insights into the DJIAMarch 14, 2024 10:51 AMView Mastering Stocks in the Dow: Insights into the DJIAMarketBeat Week in Review – 3/11 – 3/15March 16, 2024 7:00 AMView MarketBeat Week in Review – 3/11 – 3/15Okta Raises EPS Forecasts Despite High Profile Security BreachesMarch 7, 2024 6:23 AMView Okta Raises EPS Forecasts Despite High Profile Security BreachesTesla Is the Analyst's Most Downgraded Stock: How Low Can It Go?March 26, 2024 7:00 AMView Tesla Is the Analyst's Most Downgraded Stock: How Low Can It Go?Kroger Stock: Anticipating New Highs as Promising Uptrend ResumesMarch 12, 2024 7:30 AMView Kroger Stock: Anticipating New Highs as Promising Uptrend ResumesAll Headlines Company DescriptionsOncolytics BiotechTSE:ONCOncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.